9999999997-19-006364.txt : 20190802 9999999997-19-006364.hdr.sgml : 20190802 20190802091327 ACCESSION NUMBER: 9999999997-19-006364 CONFORMED SUBMISSION TYPE: CT ORDER PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20190802 DATE AS OF CHANGE: 20190802 ACTION DATE: 20190802 RECEIVED DATE: 20190802 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BELLICUM PHARMACEUTICALS, INC CENTRAL INDEX KEY: 0001358403 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 201450200 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CT ORDER SEC ACT: 1934 Act SEC FILE NUMBER: 001-36783 FILM NUMBER: 19994580 BUSINESS ADDRESS: STREET 1: 2130 WEST HOLCOMBE BOULEVARD STREET 2: SUITE 800 CITY: HOUSTON STATE: TX ZIP: 77030 BUSINESS PHONE: (832) 384-1100 MAIL ADDRESS: STREET 1: 2130 WEST HOLCOMBE BOULEVARD STREET 2: SUITE 800 CITY: HOUSTON STATE: TX ZIP: 77030 FORMER COMPANY: FORMER CONFORMED NAME: BELLICUM PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060405 CT ORDER 1 filename1.pdf begin 644 filename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